1

Zuyd University of AppliedSciences

UK

France

Germany

Limburg: a gateway to Europe

9 faculties• Bèta Sciences and Technology• Commercial and Financial Management• Health• Hotel and Facility Management• ICT• International Business and

Communication• Art• Management and Law• Social Studies and Education

48 Bachelor and Master degreeprogrammes

3 mainactivities

• Education• Research• Training

14,000 students

1,800 employees

4

Life Siences and Materials

3focus areas

Transition to a Sustainable Built Environment

Innovative Care andTechnology

3 Centresof Expertise

5

• CHILL: Chemelot Innovation andLearning Labs

• EIZT:Innovative Care andTechnology

• NEBER: New Energy, Built Environment and Renewables

6

7

Antimicrobial projects

Agenda (continued)

9. Selection of Grant Holder Institution and FSAC

10. Presentation and discussion of the AMiCI Action

11. Establishment of AMiCI Management Structure

lunch break

12. AMiCI Implementation Planning

13. Any Other Business

14. Closing

9b. The FSAC rate for the Grant Holder Institution

Financial, Scientific and Administrative Coordination

• Proposition: 15%

• To support the execution of the administrative tasks relating to managing and coordinating scientific activities

• Coordination of Action Meetings and Participation of Grant Manager at certain Action Meetings

• Reimbursements according to eligibility criteria of COST

• Preparation and delivery of reports

• Any unforeseen costs not reimbursed according to COST criteria but necessary to keep the Action running

Nosocomial infections in the media

10a. AntiMicrobial Coating Innovations to preventinfectious diseases

Socio-economic impact of failing hygiene:chances for nano

Contamination

often occurs by

transmission

from surfaces

Nanobased vs the rest

Nanotechnoloy, Science and Applications

Molling et al, Nanotechnology, Science and applications (2014)

• Shorter hospital stays

• Smaller number of re-treatment/recurrence

• Less costs related to logistics and materials related to

cleaning, chemicals, waste and equipment.

• Insurance costs as well as cost for court/lawyers

• Lower incidence of HAI and antimicrobial resistance

• A more sustainable approach

• Less cleaning costs

Better hygiene leads to reduced HAI & costs:

Antimicrobial coatings can add to:

• Effect of coatings in specific locations?

• Durability of the effect?

• New cleaning protocols?

• Compatibility with current chemicals and

procedures?

• Effect on resistant bacteria?

• New resistance mechanisms?

Need for benchmarks and information

Assessment of bacterial contamination

• Coatings judged by slow ISO-NEN protocol

(best-case, close contact needed).

• PCR can be used to rapidly (2-4 hrs)

assess presence and load of bacteria.

• New methods and equipment is needed for

Point-of-care detection of bacteria and

local intervention.

Reasons for so-far limited introduction of AMCs in healthcare

• Lack of systematic, international coördinated research on the effects of AMCs on

non-invasive materials and surfaces in healthcare

• Lack of knowledge on availability and use of different AMCs

• Insufficient information on possible adverse effects of AMCs

• Lack of standard performance assessment for AMCs in lab and field conditions or

benchmark tests

• Lack of Best Practices

10a. Main objective AMiCI

Evaluate the impact of (introducing) AntiMicrobial Coatings in

healthcare on the spread of infections and on the efficacy of

fighting Healthcare Associated Infections (HCAIs) and bacterial

resistance to current antibiotics.

AMiCI objectives / Research Coordination:

o Consult and support policy and healthcare sector regarding further actions and application of

AMC (WG3)

o Use know-how and expertise of the network to stimulate development/optimisation of

antimicrobial materials for non-invasive surfaces (WG1)

o Gather best practices and convert these into standardised methods to evaluate/compare AMC

effectiveness in lab setting, with possibilities to extrapolate to field tests (WG2)

o Gather best practices and convert these into field tests that enable evaluation of effectiveness of

the use of AMC in prevention of spread of infections in healthcare (WG2)

o Gather information on the impact of introduction of AMCs on development of multi-drug

resistance and possible development of AMR to AMCs (WG3)

o Establish approach for risk-benefit analysis for using AMCs in healthcare environments (WG3)

o Determine the effects of AMCs on the cleaning process in healthcare (WG4)

o Disseminate knowledge on AMC innovations and lab and field tests to stakeholders (WG5)

o Disseminate findings on new cleaning procedures / logistics upon introduction of AMCs into

healthcare and other sectors (WG5)

o Coordinate (inter)national research efforts to join forces in combatting AMR (WG1-2-3-4-5)

10a. Objectives Capacity Building

AMiCI objectives / Capacity Building:

o Develop and maintain a European network involving all stakeholders (producers, suppliers and

users) of AMC in healthcare and organisations involved with standards on hygiene (WG 5)

o Stimulate collaboration between industry and research institutes using available knowledge and

disclose state-of-the-art knowledge to industrial partners, leading to more effective AMC’s and

successful new market applications (WG5)

o Involvement of early-career investigators (<8 years after PhD) (WG1-2-3-4-5)

Management Committee- Chair + Vice-Chair- Scientific Representative- WG Leaders and Vice-Leaders- National Representatives

Core Group- Chair + Vice-Chair MC- WG Leaders- STSM / ECI Coordinator

WG1 WG2 WG4WG3 WG5

COST Association

Grant Holder

10b. AMiCI: Management structure

Communication CoordinatorGrants Coordinator

10b. Working Group 1

WG1 Antimicrobial materials Safe-by-Design

Reaching a conceptual understanding of the mechanisms and construction of an active and sustainable coating, to adapt current and develop new coatings to meet ECHA standards

Deliverables/Milestones - Database combining active ingredients and substrates for use of AMC in healthcare

- Exchange of unpublished AMC information between Action members on AMC development and application in healthcare

- Opinion paper on safe-by-design approaches for development and application of AMC

10b. Working Group 2

WG2 Performance assessment (lab-field-benchmark)

Development of lab and field benchmark tests to evaluate efficacy andefficiency of AMCs to reduce bacterial contamination in the environment of patients in healthcare

Deliverables/Milestones - Exchange of unpublished information on AMC lab/field tests between partners

- Benchmark test to establish efficacy and efficiency of AMCs in healthcare- Guidelines on test methods for AMC performance assessment

10b. Working Group 3

WG3 Adverse effects / Risk-benefit analysis

Focus on (eco)toxicological risks and possible introduction of AMR resulting from the use of AMC

Deliverables/Milestones - Inventory/review on current knowledge of impact of AMCs on ecosystems- Risk/benefit analysis based on inventory of available knowledge on

(eco)toxicological aspects of AMCs and possible development of AMR to AMC

- Recommendations on further development and application of AMCs in healthcare, taking into account the risk/benefit analysis

- Expert statement on further research and policy with regard to prevention of antimicrobial resistance

- Inform regulatory bodies and analytical services on risks and benefits of AMCs in healthcare

10b. Working Group 4

WG4 The new cleaning

Investigate new methods of effective cleaning, additional to the use of AMCs to ensure a safe and more hygienic future

Deliverables/Milestones - Comparison of AMC-based cleaning systems regarding safety, efficacy, sustainability and durability to the frequently used systems in healthcare

- Guidelines on new cleaning procedures, in compliance with and additional to the use of AMCs, for cleaning industries in healthcare

10b. Working Group 5

WG5 Communication and dissemination

Communicate and disseminate knowledge gathered and developed by AMICI members

Deliverables/Milestones - Project website - Database of experts in the field- Organisation of meetings and events- Participation in meetings and conferences of other networks and

stakeholders- Involvement of Framework Program policy makers to mid-term and final

Action conferences- Expansion of AMiCI network with key stakeholders including producers,

suppliers and (potential) users of AMC in healthcare and organisations involved with hygiene standards

- Exchange of ECI’s between institutes of different countries and between knowledge institutes and industry

10b. Implementation of Scientific Committee recommendations and COST policies

‘The proposed Action must develop and implement clear plans to ensure increased participation of Early Career Investigators and female researchers, and to increase the participation of academic partners.’

• After publication of MoU a lot of academic partners joint the Action

• Installation of STSM manager with specific target to involve ECI

• WG Leaders need to include ECI as WG member (proposal: >20% of each WG)

April 2016:

• 24 Countries involved, of which 11 Inclusiveness Target Countries

• 68 MC Members/substitutes, xx Early Career Investigators

• 39 males, 27 females

• 59 % academic partners (excl. research institutes, 74% incl. research institutes)

11a. Establishment of AMiCI Management Structure

ProposalPosition Candidate

Vice-Chair Minna Keinänen-Toivola (FI)

WG1 - Antimicrobial materials Safe by Design Leader Hulya Olmez (TR)

Vice-Leader Luis Melo (PT)

WG2 - Performance assessment Leader Peter Askew (UK)

Vice-Leader Birgit Teunissen (NL)

WG3 - Adverse effects / risk-benefit analysis Leader Anne Kahru (Estonia)

Vice-Leader Merja Ahonen (FI)

WG4 - The new cleaning Leader Martina Modic (Slovenia)?

Vice-Leader Ireland, Germany or Greece?

WG5 - Communication and dissemination Leader Kazimierz Murzyn (PL)

Vice-Leader Theofilos Papadopoulos (GR)

STSM / ECI Manager Isabel Gouveia (PT)

11b. Other Management (support) roles

• Communication Coordinator: Ellen de Waal – Scientific Affairs

(NL)

• Grant Writing Coordination: Raymunde Neven – Zuyd

University of Applied Science (NL)

11b. Mandates to be discussed

• Approval of STSM applications by STSM coordinator and Chair

• In case of underspending in 1 activity, the core group may

decide to use unspent funds for other COST activities

• In case of non-response, the GH can cancel non answered

invitations to meetings after 14 days of sending the invitation

12. Action implementation planning

Discussion in separate WGs:

• Deliverables

• Tasks and indicators to achieve WG objectives and deliverables

• WG members: who/which expertise is needed additionally to

achieve WG objectives and deliverables

• Objectives,tasks and deliverables during the 1st grant period

(May 1, 2016 – April 30, 2017)

See hand-out

12. Action implementation planning

COST networkingtools

Year 1 Year 2 Year 3 Year 4

MC meeting X X X X X

Core groupmeeting

X X X X X X X X

WG meeting X X X X

STSM X X X X X X X X X X X X X X

Training school X X X

Action Conference X X

Dissemination,publications

X X X X X X X X X X X X X X X X

12b. Action implementation planning: 1st Grant Period – 1 May 2016-30 April 2017

A - COST networking tools Year 1 Budget€

MC meeting (X) X

90,000Core group meeting X X

WG meeting X

Action Conference

STSM X X 7,000

Training school

Dissemination, publications X X X X 7,000

OERSA X X X X 1,200

B – Total Science expenditure 105,200

C – FSAC (15% of B) 15,780

D – Total Expenditure (B+C) 120,980

13. Any other business

• Virtual core group meetings and WG meetings via HILL

(supported by SAMK - Finland) or similar tools

• Core group meeting in Porto, before Biofilm7 conference

(26-28 June 2016)

• Dissemination meeting, launch our AMiCI COST Action @ICAR

2016 in Torremolinos-Malaga (29 June-1 July 2016)

• Next MC meeting in Maastricht, The Netherlands?

14. Closing

Thank you for your attention&let’s make AMiCI a success!